US Stock MarketDetailed Quotes
NRSN NeuroSense Therapeutics
- 1.230
- -0.070-5.38%
Close Nov 15 16:00 ET
24.36MMarket Cap-1892P/E (TTM)
1.281High1.190Low178.76KVolume1.280Open1.300Pre Close220.73KTurnover1.20%Turnover RatioLossP/E (Static)19.81MShares2.33052wk High-14.30P/B18.28MFloat Cap0.47052wk Low--Dividend TTM14.86MShs Float8.180Historical High--Div YieldTTM7.03%Amplitude0.400Historical Low1.234Avg Price1Lot Size
About NeuroSense Therapeutics Company
Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company. The firm is focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. It is involved in the 2b/3 clinical trial using its product candidate, PrimeC in patients with ALS and also commencing research into other possible indications for the drug, including Alzheimer’s and Parkinson’s diseases. The company was founded by Alon Ben-Noon on February 13, 2017 and is headquartered in Herzliya, Israel.
Company Profile
SymbolNRSN
Company NameNeuroSense Therapeutics
Listing DateDec 9, 2021
Issue Price5.99
Founded2017
CEOMr. Alon Ben-Noon
MarketNASDAQ
Employees16
Fiscal Year Ends12-31
Address11 HaMenofim Street,Building B
CityHerzliya
ProvinceTel Aviv
CountryIsrael
Zip Code46725
Phone972-9-799-6183
Websitehttp://www.neurosense-tx.com
Company Executives
- Name
- Position
- Salary
- Alon Ben-Noon
- Chief Executive Officer and Director
- 1.01M
- Or Eisenberg
- Chief Financial Officer and Principal Accounting Officer
- 1.02M
- Dr. Niva Russek-Blum
- Chief Technology Officer
- 245.00K
- Dr. Ferenc Tracik
- Chief Medical Officer
- 918.00K
- Hagit Binder
- Chief Operating Officer
- 219.00K
- Mark W. Leuchtenberger
- Chairman of the Board
- 1.48M
- Dr. Revital Mandil-Levin
- Director
- --
- Caren Deardorf
- Independent Director
- 91.00K
- Cary J Claiborne
- Independent Director
- 104.00K
- Christine A. Pellizzari
- Independent Director
- 104.00K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data